Type 1 diabetes and hearing loss: Audiometric assessment and measurement of circulating levels of soluble receptor for advanced glycation end products

Mohammed Al‐Sofiani,Sara MacLeod,Husam Ghanim,Nancy Stecker,John Hall,Howard Lippes

DOI: https://doi.org/10.1002/dmrr.3312

2020-04-19

Diabetes/Metabolism Research and Reviews

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>We examined the hearing function in adults with and without type 1 diabetes (T1D) to investigate whether an association exists between hearing loss and duration of diabetes, hemoglobin A1C level, diabetes complications, and levels of select serum and urinary biomarkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We measured pure tone audiometry (PTA) thresholds; serum levels of C‐reactive protein (CRP), vascular endothelial growth factor (VEGF), soluble receptors for advanced glycation end‐product (sRAGE); and urinary isoprostane in 30 adults with T1D (age 43.8 ±11.4 years). We also measured PTA thresholds in 11 adults without diabetes (age 53 ±5.5 years).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>63.3% of adults with T1D had high‐frequency hearing loss. Among adults with T1D, those with hearing loss were older (48.2 versus 36.2 years old, <i>p &lt;0.01</i>), had a longer duration of diabetes (30.7 versus 21.2 years, <i>p=0.02</i>), a greater prevalence of peripheral neuropathy (57.9 versus 9.1%, <i>p= 0.02</i>), and significantly lower median levels of sRAGE (1054.27 versus 1306.83 pg/ml, <i>p=0.03</i>) compared to those with normal hearing. Adults with T1D between the ages of 40 and 60 years old, who had diabetes for ≥35 years, had significantly higher PTA thresholds at both 500and 8000 Hz than age‐matched adults without diabetes. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>A significant proportion of adults with T1D have high‐frequency hearing loss before age of 60 that is positively associated with age, duration of diabetes, and presence of peripheral neuropathy. Our results are in support of previous studies suggesting a potential protective role of sRAGE against AGE toxicity and diabetes complications.</p><p>This article is protected by copyright. All rights reserved.</p></section>

What problem does this paper attempt to address?

This paper aims to explore the relationship between type 1 diabetes (T1D) and hearing loss. Specifically, the researchers evaluated the hearing function of adult patients with type 1 diabetes through pure - tone audiometry (PTA), and measured the levels of C - reactive protein (CRP), vascular endothelial growth factor (VEGF), soluble receptor for advanced glycation end products (sRAGE) in the blood of these patients and the level of isoprostanes in the urine. In addition, the association between hearing loss and diabetes duration, hemoglobin A1C (HbA1C) level, diabetes complications and the levels of the above - selected biomarkers was also evaluated.

The main objectives of the study are:
- To investigate whether there is hearing loss, especially high - frequency hearing loss, in adult patients with type 1 diabetes.
- To explore whether hearing loss is related to diabetes duration, HbA1C level, the presence of diabetes complications and the levels of specific serum and urine biomarkers.

Through this study, the author hopes to understand whether type 1 diabetes can cause or accelerate the development of hearing loss, and explore the biological mechanisms that may be involved in this process, especially the role of sRAGE in it. This will help to further understand the potential pathophysiological processes of diabetes - related hearing loss and provide a scientific basis for future prevention and treatment strategies.